Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

NCT04025632 is registered in ClinicalTrials.gov with Ra Pharmaceuticals as lead sponsor.

NCT NCT04025632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04025632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Lead sponsor
Ra Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
November 7, 2019
Completion date
June 14, 2021
Enrollment
27 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

immune mediated necrotizing myopathy